299 related articles for article (PubMed ID: 33274239)
1. The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy.
Sha W; Wen S; Chen L; Xu B; Lei T; Zhou L
J Diabetes Res; 2020; 2020():8867875. PubMed ID: 33274239
[TBL] [Abstract][Full Text] [Related]
2. Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy.
Cho EH; Park SJ; Han S; Song JH; Lee K; Chung YR
J Diabetes Res; 2018; 2018():6807219. PubMed ID: 30622970
[TBL] [Abstract][Full Text] [Related]
3. Do SGLT2 inhibitors prevent preclinical diabetic retinopathy? A Prospective Pilot Optical Coherence Tomography Angiography Study.
Sabaner MC; Duman R; Dogan M; Akdogan M; Vurmaz A; Bozkurt E; Beysel S
J Fr Ophtalmol; 2021 Oct; 44(8):1159-1167. PubMed ID: 34244004
[TBL] [Abstract][Full Text] [Related]
4. Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy.
Matthews J; Herat L; Rooney J; Rakoczy E; Schlaich M; Matthews VB
Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35234250
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel Hypothesis.
Mudaliar S; Hupfeld C; Chao DL
J Clin Endocrinol Metab; 2021 Apr; 106(5):1235-1244. PubMed ID: 33512450
[TBL] [Abstract][Full Text] [Related]
6. The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders: a systematic review and meta-analysis.
Ma Y; Lin C; Cai X; Hu S; Zhu X; Lv F; Yang W; Ji L
Expert Rev Clin Pharmacol; 2022 Jul; 15(7):877-886. PubMed ID: 35839519
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.
Takata T; Isomoto H
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922132
[TBL] [Abstract][Full Text] [Related]
9. Optimising renal risk parameters in type 2 diabetes mellitus: Perspectives from a retinal viewpoint.
Jacob S; Varughese GI
Clin Med (Lond); 2024 Mar; 24(2):100031. PubMed ID: 38369127
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
11. Sodium-glucose cotransporter 2 inhibitors (SGLT2i): renal implications.
Castañeda AM; Dutra-Rufato A; Juarez MJ; Grosembacher L; Gonzalez-Torres H; Musso CG
Int Urol Nephrol; 2021 Feb; 53(2):291-299. PubMed ID: 32767250
[TBL] [Abstract][Full Text] [Related]
12. [SGLT2 inhibitors in diabetic and non-diabetic nephropathies].
Scheen M; Zanchi A; Martin PY; De Seigneux S
Rev Med Suisse; 2021 Feb; 17(727):378-382. PubMed ID: 33625802
[TBL] [Abstract][Full Text] [Related]
13. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
14. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
15. Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
Sano M
Intern Med; 2020 Jan; 59(1):1-5. PubMed ID: 31178515
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.
Górriz JL; Navarro-González JF; Ortiz A; Vergara A; Nuñez J; Jacobs-Cachá C; Martínez-Castelao A; Soler MJ
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i13-i23. PubMed ID: 32003834
[TBL] [Abstract][Full Text] [Related]
17. The effect of total lignans from Fructus Arctii on Streptozotocin-induced diabetic retinopathy in Wistar rats.
Zhang H; Gao Y; Zhang J; Wang K; Jin T; Wang H; Ruan K; Wu F; Xu Z
J Ethnopharmacol; 2020 Jun; 255():112773. PubMed ID: 32199990
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists treatment: variable observations of sequelae on diabetic retinopathy.
Varughese GI; Jacob S
J R Soc Med; 2023 Dec; 116(12):408. PubMed ID: 38054392
[No Abstract] [Full Text] [Related]
19. An innovative method for screening and evaluating the degree of diabetic retinopathy and drug treatment based on artificial intelligence algorithms.
Xie Q; Liu Y; Huang H; Hong B; Wang J; Han H; Liu Y
Pharmacol Res; 2020 Sep; 159():104986. PubMed ID: 32502641
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
Chung YR; Ha KH; Lee K; Kim DJ
PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
